Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry
Jazyk angličtina Země Francie Médium print-electronic
Typ dokumentu časopisecké články
- MeSH
- antitumorózní látky terapeutické užití MeSH
- databáze faktografické MeSH
- dospělí MeSH
- fenylmočovinové sloučeniny terapeutické užití MeSH
- Kaplanův-Meierův odhad MeSH
- karcinom z renálních buněk diagnóza farmakoterapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- metastázy nádorů MeSH
- mladý dospělý MeSH
- multivariační analýza MeSH
- nádory ledvin diagnóza farmakoterapie MeSH
- niacinamid analogy a deriváty terapeutické užití MeSH
- přežití po terapii bez příznaků nemoci MeSH
- prognóza MeSH
- proporcionální rizikové modely MeSH
- registrace MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- sorafenib MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Česká republika MeSH
- Názvy látek
- antitumorózní látky MeSH
- fenylmočovinové sloučeniny MeSH
- niacinamid MeSH
- sorafenib MeSH
The aim of this study was to describe the characteristics and outcomes of a large cohort of patients treated with sorafenib in clinical practice and to identify predictive factors associated with prognosis. Patient data were obtained from the national Czech registry (RenIS). Data of virtually all Czech patients receiving targeted therapies are entered into this non-interventional post-registration database. Demographics and clinical data, as well as all treatment sequences and clinical outcomes, are reported in this registry. A total of 836 patients treated with sorafenib before March 2013 were included in the analysis. Median age was 63 years and 70% were men. Most patients had received prior treatment with cytokines, sunitinib or both. Sorafenib was the first-line treatment in 15% of patients. Median overall survival and progression-free survival were 21.7 months and 7.5 months, respectively. Median overall survival and progression-free survival was 26.3 and 8.3 months, respectively, in patients receiving sorafenib as first-line therapy. Cox proportional models identified several parameters associated with poor outcome including time ≤1 year from diagnosis to first-line systemic treatment, performance status ≥2, low hemoglobin, and LDH >1.5 times the upper limit of normal. Our data demonstrate that the outcomes of real-life patients are comparable to those enrolled in clinical trials. Prognostic factors identified in the present study were consistent with previously reported models.
Zobrazit více v PubMed
BJU Int. 2011 Dec;108(11):1813-9 PubMed
J Clin Oncol. 2014 Mar 10;32(8):760-7 PubMed
Ann Oncol. 2011 Feb;22(2):295-300 PubMed
Cancer. 1987 Feb 1;59(3 Suppl):647-51 PubMed
Chemotherapy. 2012;58(6):468-74 PubMed
Ann Oncol. 2012 Feb;23(2):395-401 PubMed
J Clin Oncol. 2009 Mar 10;27(8):1280-9 PubMed
Lancet Oncol. 2014 Mar;15(3):286-96 PubMed
Ann Oncol. 2012 Oct;23 Suppl 7:vii65-71 PubMed
J Natl Compr Canc Netw. 2011 Sep 1;9(9):960-77 PubMed
Eur Urol. 2013 Feb;63(2):254-61 PubMed
Lancet Oncol. 2013 Dec;14(13):1287-94 PubMed
Lancet. 2009 Mar 28;373(9669):1119-32 PubMed
BJU Int. 2011 Nov;108(10):1556-63 PubMed
Med Oncol. 2012 Dec;29(5):3314-20 PubMed
Clin Cancer Res. 2006 Dec 15;12(24):7271-8 PubMed
J Clin Oncol. 2006 Jun 1;24(16):2505-12 PubMed
Lancet. 2011 Dec 3;378(9807):1931-9 PubMed
N Engl J Med. 2007 Jan 11;356(2):125-34 PubMed
J Natl Compr Canc Netw. 2011 Feb;9 Suppl 1:S1-29 PubMed
J Clin Oncol. 2002 Jan 1;20(1):289-96 PubMed
Oncology. 2012;82(6):333-40 PubMed
J Clin Oncol. 2009 Jul 10;27(20):3312-8 PubMed
